OPCH Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Net Revenue: $5.6 billion, up 13% year-over-year, driven by growth in both acute (mid-teens) and chronic therapies (low double digits).
Gross Profit: Increased by 7.4%.
Adjusted EBITDA: $471 million, a 6% increase, with an EBITDA margin of 8.3%.
Adjusted Diluted EPS: $1.72, reflecting a 9% growth.
Cash Flow from Operations: $258 million for the year.
Net Debt to Leverage Ratio: 2.0x.
2026 Operating Cash Flow Guidance: Expected to exceed $340 million.

2. Strategic Updates and Business Highlights

OPCH is the largest independent provider of home and alternate site infusion therapy, serving over 315,000 unique patients in 2025.
Expanded partnerships with payers, adding 5 new programs with regional health plans and 2 with nontraditional payers.
Continued investment in technology, including AI for claims processing, which now automates approximately 40% of claims.
Growth in ambulatory infusion clinics, with a 25% increase in visits at Intramed Plus sites.
Focus on expanding the formulary with new infused and injectable drugs, particularly in rare and orphan products.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Expected between $5.8 billion and $6 billion, reflecting a 4% growth at the midpoint, with a 400 basis point headwind from Stelara and its biosimilars.
Adjusted EBITDA Guidance: Projected between $480 million and $505 million, including a $25 million to $35 million gross profit headwind from Stelara.
Adjusted Diluted EPS Guidance: Expected between $1.82 and $1.92.

4. Bad News, Challenges, or Points of Concern

Headwinds from Stelara: Transition to biosimilars is expected to impact revenue and gross profit, with a significant headwind noted for 2026.
Working Capital Management: Increased working capital needs due to strategic inventory purchases and investments in limited distribution therapies.
Competitive Landscape: While OPCH has benefited from competitors exiting the market, the landscape is stabilizing, and future growth may be more challenging.
Regulatory Risks: Potential concerns surrounding the 340B program and its implications for revenue.

5. Notable Q&A Insights

Payer Relationships: Conversations with payers are increasing, focusing on affordability and total cost of care management.
Advanced Practitioner Model: Growth in advanced practitioner sites is ongoing, with a focus on both new and existing locations.
Biosimilar Impact: The company remains cautious but optimistic about the impact of Stelara and other biosimilars, with no significant changes to guidance expected.
M&A Strategy: OPCH is actively seeking complementary acquisitions while maintaining a disciplined approach to ensure strategic and financial alignment.
AI Applications: Beyond claims processing, OPCH is exploring AI for workforce optimization and customer service enhancements.

Overall, OPCH demonstrated strong financial performance in 2025, with a solid outlook for 2026 despite headwinds from biosimilars and ongoing competitive pressures. The company is strategically positioned to leverage its capabilities in home and alternate site infusion therapy while navigating challenges in the healthcare landscape.

OPCH — Option Care Health, Inc.